Should I buy or sell CollPlant Biotechnologies stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CollPlant Biotechnologies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLGN shares. View CLGN analyst ratings or view top-rated stocks .

What is CollPlant Biotechnologies' stock price target for 2024?

1 brokers have issued 12 month price targets for CollPlant Biotechnologies' stock. Their CLGN share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 110.7% from the stock's current price. View analysts price targets for CLGN or view top-rated stocks among Wall Street analysts .

How have CLGN shares performed in 2024?

CollPlant Biotechnologies' stock was trading at $6.39 on January 1st, 2024. Since then, CLGN stock has decreased by 18.3% and is now trading at $5.22. View the best growth stocks for 2024 here .

Are investors shorting CollPlant Biotechnologies?

CollPlant Biotechnologies saw a increase in short interest in March. As of March 31st, there was short interest totaling 10,800 shares, an increase of 33.3% from the March 15th total of 8,100 shares. Based on an average daily trading volume, of 8,200 shares, the short-interest ratio is currently 1.3 days. Currently, 0.1% of the shares of the stock are sold short. View CollPlant Biotechnologies' Short Interest .

When is CollPlant Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024. View our CLGN earnings forecast .

How were CollPlant Biotechnologies' earnings last quarter?

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) posted its earnings results on Thursday, August, 24th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.83. The company had revenue of $10.18 million for the quarter, compared to analyst estimates of $0.26 million. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 22.17% and a negative net margin of 64.05%. During the same quarter in the prior year, the business earned ($0.39) EPS.

What other stocks do shareholders of CollPlant Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CollPlant Biotechnologies investors own include Genocea Biosciences (GNCA) , Boingo Wireless (WIFI) , Allena Pharmaceuticals (ALNA) , Advanced Micro Devices (AMD) , Energy Transfer (ET) , HTG Molecular Diagnostics (HTGM) , OPKO Health (OPK) , Ovid Therapeutics (OVID) and

When did CollPlant Biotechnologies IPO?

CollPlant Biotechnologies (CLGN) raised $22 million in an initial public offering (IPO) on Friday, December 9th 2016. The company issued 3,500,000 shares at a price of $6.23 per share. Ladenburg Thalmann acted as the underwriter for the IPO and Roth Capital Partners was co-manager.

How do I buy shares of CollPlant Biotechnologies?

Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CLGN

CollPlant Biotechnologies (CLGN) Stock Price, News & Analysis

→ 3 Sub-$10 Stocks to Buy for 2024 (From TradingTips) (Ad)

Free CLGN Stock Alerts

$5.22

-0.02 (-0.38%)

(As of 04/18/2024 ET)

Compare

Today's Range: $5.10
▼
$5.24
50-Day Range: $4.71
▼
$5.68
52-Week Range: $4.22
▼
$8.90

Volume: 8,592 shs
Average Volume: 5,524 shs
Market Capitalization: $59.77 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

Get CollPlant Biotechnologies alerts:

CollPlant Biotechnologies MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 110.7% Upside
$11.00 Price Target
Short Interest: Healthy
0.14% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.46
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.42) to ($0.52) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.88 out of 5 stars

Medical Sector

616th out of 918 stocks

Surgical Appliances & Supplies Industry

14th out of 18 stocks

3.5

Analyst's Opinion

Consensus Rating
CollPlant Biotechnologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
CollPlant Biotechnologies has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.14% of the float of CollPlant Biotechnologies has been sold short.
Short Interest Ratio / Days to Cover
CollPlant Biotechnologies has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in CollPlant Biotechnologies has recently increased by 33.33%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
CollPlant Biotechnologies does not currently pay a dividend.
Dividend Growth
CollPlant Biotechnologies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CLGN.

3.0

News and Social Media Coverage

News Sentiment
CollPlant Biotechnologies has a news sentiment score of 1.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for CollPlant Biotechnologies this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 1 people have added CollPlant Biotechnologies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CollPlant Biotechnologies insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.60% of the stock of CollPlant Biotechnologies is held by insiders.
Percentage Held by Institutions
Only 21.69% of the stock of CollPlant Biotechnologies is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for CollPlant Biotechnologies are expected to grow in the coming year, from ($1.42) to ($0.52) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of CollPlant Biotechnologies is -8.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of CollPlant Biotechnologies is -8.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
CollPlant Biotechnologies has a P/B Ratio of 2.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About CollPlant Biotechnologies Stock (NASDAQ:CLGN)

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; injectable implants to promote breast tissue regeneration; 3D bioprinted regenerative soft tissue matrix; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has collaboration agreements with 3D Systems Corporation; CellInk, a BICO Group company; Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; Israel's Technion Institute of Technology; Tel Aviv University; Sheba Medical Center; AbbVie; and STEMCELL. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

CLGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CLGN Stock News Headlines

April 15, 2024 | americanbankingnews.com

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Update

April 8, 2024 | msn.com

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q4 2023 Earnings Call Transcript

April 19, 2024 | DTI (Ad)

Start loving Mondays like this

Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!

April 6, 2024 | seekingalpha.com

CollPlant Biotechnologies Ltd. (CLGN) Q4 2023 Earnings Call Transcript

April 4, 2024 | markets.businessinsider.com

CollPlant Biotechnologies FY23 Net Loss Narrows

April 4, 2024 | msn.com

CLGN Stock Earnings: CollPlant Biotechnologies Misses EPS, Misses Revenue for Q4 2023

April 4, 2024 | msn.com

US Index Futures Rise, Oil Dips Slightly

April 4, 2024 | prnewswire.com

COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

April 19, 2024 | DTI (Ad)

Start loving Mondays like this

March 26, 2024 | finance.yahoo.com

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

February 15, 2024 | finance.yahoo.com

CollPlant Issues Letter to Shareholders

February 15, 2024 | prnewswire.com

CollPlant Issues Letter to Shareholders

February 13, 2024 | au.finance.yahoo.com

COLLPLANT BIOTECH. IS-,01 (CPT.MU)

January 8, 2024 | finance.yahoo.com

CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California

January 2, 2024 | finance.yahoo.com

CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants

December 2, 2023 | benzinga.com

CollPlant Biotechnologies Stock (NASDAQ:CLGN), Analyst Ratings, Price Targets, Predictions

December 1, 2023 | finance.yahoo.com

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Q3 2023 Earnings Call Transcript

November 29, 2023 | benzinga.com

Recap: CollPlant Biotechnologies Q3 Earnings

November 29, 2023 | msn.com

CollPlant Biotechnologies Non-GAAP EPS of -$0.35

November 29, 2023 | finance.yahoo.com

CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023

November 9, 2023 | finance.yahoo.com

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

November 3, 2023 | finance.yahoo.com

Will CollPlant Biotechnologies (NASDAQ:CLGN) Spend Its Cash Wisely?

November 1, 2023 | msn.com

CollPlant says patent granted in U.S. for photocurable dermal filler

November 1, 2023 | finance.yahoo.com

CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler

October 5, 2023 | finance.yahoo.com

Shareholders in CollPlant Biotechnologies (NASDAQ:CLGN) are in the red if they invested three years ago

September 21, 2023 | finance.yahoo.com

CollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability Initiative

September 5, 2023 | finance.yahoo.com

CollPlant to Present at the H.C. Wainwright Annual Growth Conference

See More Headlines

Receive CLGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CollPlant Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/24/2023
Today: 4/18/2024
Next Earnings (Estimated): 5/22/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical appliances & supplies
Sub-Industry: N/A
Current Symbol: NASDAQ:CLGN
CUSIP: N/A
CIK: 1631487
Web: www.collplant.com
Phone: 972732325600
Fax: 972-73-232-5602
Employees: 73
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.00
High Stock Price Target: $11.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +109.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.64)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-7,020,000.00
Net Margins: -64.05%
Pretax Margin: -64.05%
Return on Equity: -22.17%
Return on Assets: -18.84%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.62
Quick Ratio: 8.40

Sales & Book Value

Annual Sales: $10.96 million
Price / Sales: 5.47
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.47 per share
Price / Book: 2.12

Miscellaneous

Outstanding Shares: 11,450,000
Free Float: 10,354,000
Market Cap: $60.00 million
Optionable: Optionable
Beta: 0.24

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Mr. Yehiel Tal (Age 72)
CEO & Director
Comp: $865k
Mr. Eran Rotem CPA (Age 56)
Deputy CEO & CFO
Comp: $651k
Prof. Oded Shoseyov (Age 68)
Founder & Chief Scientist
Comp: $384k
Mr. Oren Fahimipoor (Age 42)
Vice President of Operations
Ms. Hadas Dreiher Horowitz (Age 47)
Vice President of Human Resources
Dr. Elana Gazal (Age 49)
Vice President of Research & Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

CLGN Stock Analysis - Frequently Asked Questions

Should I buy or sell CollPlant Biotechnologies stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CollPlant Biotechnologies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLGN shares.
View CLGN analyst ratings or view top-rated stocks.
What is CollPlant Biotechnologies' stock price target for 2024?: 1 brokers have issued 12 month price targets for CollPlant Biotechnologies' stock. Their CLGN share price targets range from $11.00 to $11.00. On average, they predict the company's stock price to reach $11.00 in the next year. This suggests a possible upside of 110.7% from the stock's current price.
View analysts price targets for CLGN or view top-rated stocks among Wall Street analysts.
How have CLGN shares performed in 2024?: CollPlant Biotechnologies' stock was trading at $6.39 on January 1st, 2024. Since then, CLGN stock has decreased by 18.3% and is now trading at $5.22.
View the best growth stocks for 2024 here.
Are investors shorting CollPlant Biotechnologies?: CollPlant Biotechnologies saw a increase in short interest in March. As of March 31st, there was short interest totaling 10,800 shares, an increase of 33.3% from the March 15th total of 8,100 shares. Based on an average daily trading volume, of 8,200 shares, the short-interest ratio is currently 1.3 days. Currently, 0.1% of the shares of the stock are sold short.
View CollPlant Biotechnologies' Short Interest.
When is CollPlant Biotechnologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024.
View our CLGN earnings forecast.

How were CollPlant Biotechnologies' earnings last quarter?: CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) posted its earnings results on Thursday, August, 24th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.83. The company had revenue of $10.18 million for the quarter, compared to analyst estimates of $0.26 million. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 22.17% and a negative net margin of 64.05%. During the same quarter in the prior year, the business earned ($0.39) EPS.
What other stocks do shareholders of CollPlant Biotechnologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other CollPlant Biotechnologies investors own include Genocea Biosciences (GNCA), Boingo Wireless (WIFI), Allena Pharmaceuticals (ALNA), Advanced Micro Devices (AMD), Energy Transfer (ET), HTG Molecular Diagnostics (HTGM), OPKO Health (OPK), Ovid Therapeutics (OVID) and
When did CollPlant Biotechnologies IPO?: CollPlant Biotechnologies (CLGN) raised $22 million in an initial public offering (IPO) on Friday, December 9th 2016. The company issued 3,500,000 shares at a price of $6.23 per share. Ladenburg Thalmann acted as the underwriter for the IPO and Roth Capital Partners was co-manager.
How do I buy shares of CollPlant Biotechnologies?: Shares of CLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLGN) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial